Clinical Research Directory

Inclusion Criteria: * Written informed consent * Male and female patients at least 18 years of age * Newly diagnosed Stage IIIB/C or IV non-small cell lung cancer (according to Revised Cancer Staging by American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) 8th edition) or recurrent non-small cell lung cancer (NSCLC) * Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC * Presence of at least 1 measurable tumour as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Neutrophils ≥ 1,5 × 10\^9/L * Platelets ≥ 100 × 10\^9/L * Haemoglobin ≥ 90 g/L * Bilirubin level ≤ 1.5 × upper limit of normal (ULN) * Aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) levels \< 3 × ULN (\< 5 × ULN for patients with liver metastases) * Alkaline phosphatase level \< 3 × ULN (\< 5 × ULN for patients with liver or bone metastases) Exclusion Criteria: * Known sensitizing EGFR mutations or ALK translocation positive mutations * Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that is likely to bleed * Major surgery 28 days before inclusion into the study * Minor surgery 7 days before inclusion into the study * Stage II or higher of neuropathy or ototoxicity according to Common Terminology Criteria for Adverse Events (CTCAE) v.5.0, excluding trauma * Life expectancy less than 6 months * Metastases to central nervous system or carcinomatous meningitis * Pregnancy or lactation